CompletedPhase 1ketamine
Multiple Dose Pharmacokinetics of Intranasal Ketamine
Sponsored by Javelin Pharmaceuticals
NCT ID
NCT00519987
Target Enrollment
18 participants
Start Date
2007-06
Est. Completion
2007-08
About This Study
This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
Conditions Studied
Interventions
- •intranasal ketamine
Eligibility
Age:18 Years - N/A
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * Healthy adults Exclusion Criteria: * under 18 years